OSE Immunotherapeutics has received a French government grant to support a Phase III clinical trial for its cancer vaccine, Tedopi. The trial will focus on patients with advanced non-small cell lung cancer (NSCLC) who have not responded to previous treatments. Tedopi is designed to stimulate the immune system to target specific tumor cells, offering a new potential treatment option for those with limited alternatives. The funding underscores France’s commitment to advancing innovative cancer therapies.
OSE Secures French Government Grant for Phase III for non-small cell lung cancer Vaccine Trial
Help us improve this article
- Add a clear point? Share it in comment.
- Spot an error? Provide the correction and source.
- Broken link? Share a working alternative.
Your feedback helps keep the content accurate and valuable.